AIM: This study aimed to evaluate the efficacy and safety of sofosbuvir (SOF)/ribavirin (RBV) and SOF/daclatasvir (DAC)/ RBV in Egyptian patients with hepatitis C virus (HCV)-related cirrhosis and to demonstrate the effects of these treatments on their haematological and biochemical profiles. PATIENTS AND METHODS: A prospective study was performed on 200 patients with HCV-related cirrhosis. Group 1 received SOF and RBV for 24 weeks, and Group 2 received SOF, DAC and RBV for 12 weeks. RESULTS: A sustained virological response (SVR) was achieved in 75 (75%) and 96 (96%) patients in Groups 1 and 2, respectively. The mean haemoglobin (Hb) level and platelet count decreased significantly at the end of treatment in both groups, and the percent decrease was significantly higher in Group 1 than in Group 2. The mean albumin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) levels decreased significantly at the end of treatment in both groups. There was a significant increase in the mean total bilirubin level in both groups at the end of treatment. The percent increase in the mean indirect bilirubin level was significantly higher in Group 2 than in Group 1. There was improvement in the Fibrosis-4 (FIB-4) score at the end of treatment in both groups. This improvement was maintained to SVR 12 in both groups. CONCLUSION: Patients with cirrhosis who received SOF, DAC and RBV for 12 weeks had a significantly higher SVR12 rate than those who received SOF and RBV for 24 weeks. In patients who achieved SVR, there was improvement in liver function parameters and the FIB4 score at the time of SVR12 in compared to baseline values.